公开(公告)号：US20230058588A1

公开(公告)日：2023-02-23

申请号：US17892804

申请日：2022-08-22

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Ke Zhang ,  Maher Albitar

IPC: C12Q1/6886 ,  G01N33/574

Abstract: Provided herein are methods for the diagnosis, or management of liver diseases, e.g.. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

公开(公告)号：US11421283B2

公开(公告)日：2022-08-23

申请号：US16577491

申请日：2019-09-20

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Ke Zhang ,  Maher Albitar

IPC: C12Q1/6886 ,  G01N33/574

Abstract: Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

公开(公告)号：US11275088B2

公开(公告)日：2022-03-15

申请号：US16989125

申请日：2020-08-10

Applicant: Quest Diagnostics Investments LLC

Inventor： Maher Albitar

IPC: C12Q1/6883 ,  G01N33/574 ,  A61K31/497 ,  A61K31/506 ,  C07K14/82 ,  C12N9/12

Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.

公开(公告)号：US20190112662A1

公开(公告)日：2019-04-18

申请号：US16153094

申请日：2018-10-05

Applicant: Quest Diagnostics Investments LLC

Inventor： Maher Albitar ,  Wanlong Ma

IPC: C12Q1/6883 ,  C12Q1/6816 ,  C12Q1/686 ,  G01N33/574

Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.

公开(公告)号：US20210198751A1

公开(公告)日：2021-07-01

申请号：US17204227

申请日：2021-03-17

Applicant: Quest Diagnostics Investments LLC

Inventor： Maher Albitar ,  Wanlong Ma

IPC: C12Q1/6886 ,  C12N9/12 ,  C12Q1/6883 ,  G01N33/573 ,  C12Q1/6869

Abstract: The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.

公开(公告)号：US20200209242A1

公开(公告)日：2020-07-02

申请号：US16736325

申请日：2020-01-07

Applicant: Quest Diagnostics Investments LLC

Inventor： Jean Marie Bruey ,  Maher Albitar

IPC: G01N33/574

Abstract: The present invention provides methods and compositions for detection, diagnosis, prognosis, monitoring treatment and monitoring progression of cancer by detecting the level of Ki-67 protein in an individual.

公开(公告)号：US20190100807A1

公开(公告)日：2019-04-04

申请号：US16158854

申请日：2018-10-12

Applicant: Quest Diagnostics Investments LLC

Inventor： Maher Albitar ,  Wanlong Ma

IPC: C12Q1/6886 ,  C12Q1/6869 ,  C12N9/12 ,  G01N33/573 ,  C12Q1/6883

Abstract: The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.

公开(公告)号：US20190064170A1

公开(公告)日：2019-02-28

申请号：US16118874

申请日：2018-08-31

Applicant: Quest Diagnostics Investments LLC

Inventor： Maher Albitar

IPC: G01N33/574 ,  G01N33/68

Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.

公开(公告)号：US20230416835A1

公开(公告)日：2023-12-28

申请号：US18141862

申请日：2023-05-01

Applicant: Quest Diagnostics Investments LLC

Inventor： Heather R. Sanders ,  Maher Albitar ,  Aurelia Meloni-Ehrig

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/16 ,  C07K16/40

Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

公开(公告)号：US20210011019A1

公开(公告)日：2021-01-14

申请号：US17026766

申请日：2020-09-21

Applicant: Quest Diagnostics Investments LLC

Inventor： Wanlong MA ,  Maher Albitar

IPC: G01N33/574 ,  C12Q1/6883

Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.